854
Views
99
CrossRef citations to date
0
Altmetric
Clinical Trial Report

Potential Clinical Benefits of Quercetin in the Early Stage of COVID-19: Results of a Second, Pilot, Randomized, Controlled and Open-Label Clinical Trial

ORCID Icon, , , , , ORCID Icon, ORCID Icon, , , ORCID Icon, ORCID Icon & show all
Pages 2807-2816 | Published online: 24 Jun 2021

References

  • Bulut C, Kato Y. Epidemiology of COVID-19. Turk J Med Sci. 2020;50(SI–1):563–570. doi:10.3906/sag-2004-172
  • Sharma O, Sultan AA, Ding H, Triggle CR. A Review of the progress and challenges of developing a vaccine for COVID-19. Front Immunol. 2020;11:585354. doi:10.3389/fimmu.2020.585354
  • Singh SP, Pritam M, Pandey B, Yadav TP. Microstructure, pathophysiology, and potential therapeutics of COVID-19: a comprehensive review. J Med Virol. 2021;93(1):275–299. doi:10.1002/jmv.26254
  • Jean SS, Lee PI, Hsueh PR. Treatment options for COVID-19: the reality and challenges. J Microbiol Immunol Infect. 2020;53(3):436–443. doi:10.1016/j.jmii.2020.03.034
  • Shanmugaraj B, Siriwattananon K, Wangkanont K, Phoolcharoen W. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pac J Allergy Immunol. 2020;38(1):10–18. doi:10.12932/AP-200220-0773
  • Toniati P, Piva S, Cattalini M, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyper-inflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy. Autoimmun Rev. 2020;19(7):102568. doi:10.1016/j.autrev.2020.102568
  • Suter F, Consolaro E, Pedroni S, et al. A simple, home-therapy algorithm to prevent hospitalization for covid-19 patients: a retrospective observational matched-cohort study. medRxiv Preprint. doi:10.1101/2021.03.25.21254296
  • Hu B, Huang S, Yin L. The cytokine storm and COVID-19. J Med Virol. 2021;93(1):250–256. doi:10.1002/jmv.26232
  • Jamilloux Y, Henry T, Belot A, et al. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmun Rev. 2020;19(7):102567. doi:10.1016/j.autrev.2020.102567
  • Derosa G, Maffioli P, D’Angelo A, Di Pierro F. A role for quercetin in coronavirus disease 2019 (COVID-19). Phytother Res. 2021;35(3):1230–1236. doi:10.1002/ptr.6887
  • D’Andrea G. Quercetin: a flavonol with multifaceted therapeutic applications? Fitoterapia. 2015;106:256–271. doi:10.1016/j.fitote.2015.09.018
  • Taslidere E, Dogan Z, Elbe H, Vardi N, Cetin A, Turkoz Y. Quercetin protection against ciprofloxacin induced liver damage in rats. Biotech Histochem. 2016;91(2):116–121. doi:10.3109/10520295.2015.1085093
  • Ullah A, Munir S, Badshah SL, et al. Important flavonoids and their role as a therapeutic agent. Molecules. 2020;25(22):5243. doi:10.3390/molecules25225243
  • Li Y, Yao J, Han C, et al. Quercetin, inflammation and immunity. Nutrients. 2016;8(3):167. doi:10.3390/nu8030167
  • Moradian N, Gouravani M, Salehi MA, et al. Cytokine release syndrome: inhibition of pro-inflammatory cytokines as a solution for reducing COVID-19 mortality. Eur Cytokine Netw. 2020;31(3):81–93. doi:10.1684/ecn.2020.0451
  • Chen W, Zheng KI, Liu S, Yan Z, Xu C, Qiao Z. Plasma CRP level is positively associated with the severity of COVID-19. Ann Clin Microbiol Antimicrob. 2020;19(1):18. doi:10.1186/s12941-020-00362-2
  • Mohammadi-Sartang M, Mazloom Z, Sherafatmanesh S, Ghorbani M, Firoozi D. Effects of supplementation with quercetin on plasma C-reactive protein concentrations: a systematic review and meta-analysis of randomized controlled trials. Eur J Clin Nutr. 2017;71(9):1033–1039. doi:10.1038/ejcn.2017.55
  • Tanaka Y, Furuta A, Asano K, Kobayashi H. Modulation of Th1/Th2 cytokine balance by quercetin in vitro. Medicines (Basel). 2020;7(8):46. doi:10.3390/medicines7080046
  • Bae JH, Kim JY, Kim MJ, et al. Quercetin enhances susceptibility to NK cell-mediated lysis of tumor cells through induction of NKG2D ligands and suppression of HSP70. J Immunother. 2010;33(4):391–401. doi:10.1097/CJI.0b013e3181d32f22
  • Zhou L, Huntington K, Zhang S, et al. Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells. bioRxiv [Preprint]. 2020;2020. doi:10.1101/2020.08.02.230839.
  • Brito JCM, Lima WG, Cordeiro LPB, da Cruz Nizer WS. Effectiveness of supplementation with quercetin-type flavonols for treatment of viral lower respiratory tract infections: systematic review and meta-analysis of preclinical studies. Phytother Res. 2021. doi:10.1002/ptr.7122
  • Gao L, Liu G, Wang X, Liu F, Xu Y, Ma J. Preparation of a chemically stable quercetin formulation using nanosuspension technology. Int J Pharm. 2011;404(1–2):231–237. doi:10.1016/j.ijpharm.2010.11.009
  • Wang W, Sun C, Mao L, et al. The biological activities, chemical stability, metabolism, and delivery systems of quercetin: a review. Trends Food Sci Technol. 2016;56:21–38. doi:10.1016/j.tifs.2016.07.004
  • Riva A, Ronchi M, Petrangolini G, Bosisio S, Allegrini P. Improved Oral Absorption of quercetin from quercetin phytosome®, a new delivery system based on food grade lecithin. Eur J Drug Metab Pharmacokinet. 2019;44(2):169–177. doi:10.1007/s13318-018-0517-3
  • Di Pierro F, Khan A, Bertuccioli A, et al. Quercetin Phytosome® as a potential candidate for managing COVID-19. Minerva Gastroenterol Dietol. 2020. doi:10.23736/S1121-421X.20.02771-3
  • Yang BY, Barnard LM, Emert JM. Clinical characteristics of patients with coronavirus disease 2019 (COVID-19) receiving emergency medical services in King County, Washington. JAMA Netw Open. 2020;3(7):7. doi:10.1001/jamanetworkopen.2020.14549
  • Argenziano MG, Bruce SL, Slater CL. Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series. BMJ. 2020;369:m1996. doi:10.1136/bmj.m1996
  • McCullough PA, Kelly RJ, Ruocco G, et al. Pathophysiological basis and rationale for early outpatient treatment of SARS-CoV-2 (COVID-19) infection. Am J Med. 2021;134(1):16–22. doi:10.1016/j.amjmed.2020.07.003
  • Holford P, Carr AC, Jovic TH, et al. Vitamin C-an adjunctive therapy for respiratory infection, sepsis and COVID-19. Nutrients. 2020;12(12):3760. doi:10.3390/nu12123760
  • Chang R, Ng TB, Sun WZ. Lactoferrin as potential preventative and adjunct treatment for COVID-19. Int J Antimicrob Agents. 2020;56(3):106118. doi:10.1016/j.ijantimicag.2020.106118
  • Colunga Biancatelli RML, Berrill M, Catravas JD, Marik PE. Quercetin and vitamin C: an experimental, synergistic therapy for the prevention and treatment of SARS-CoV-2 related disease (COVID-19). Front Immunol. 2020;11:1451. doi:10.3389/fimmu.2020.01451
  • Diniz LRL, Souza MTS, Duarte ABS, Sousa DP. Mechanistic aspects and therapeutic potential of quercetin against COVID-19-associated acute kidney injury. Molecules. 2020;25(23):5772. doi:10.3390/molecules25235772
  • Farina N, Ramirez GA, De Lorenzo R, et al. COVID-19: pharmacology and kinetics of viral clearance. Pharmacol Res. 2020;161:105114. doi:10.1016/j.phrs.2020.105114
  • Di Pierro F, Derosa G, Maffioli P, et al. Possible therapeutic effects of adjuvant quercetin supplementation against early stage COVID-19 infection: a prospective, randomized, controlled, and open-label study. Int J Gen Med. 2021;14:1–8. doi:10.2147/IJGM.S318720
  • Guan X, Zhang B, Fu M, et al. Clinical and inflammatory features-based machine learning model for fatal risk prediction of hospitalized COVID-19 patients: results from a retrospective cohort study. Ann Med. 2021;53(1):257–266. doi:10.1080/07853890.2020.1868564
  • Vicidomini C, Roviello V, Roviello GN. Molecular basis of the therapeutical potential of clove (Syzygium aromaticum L.) and clues to its anti-COVID-19 utility. Molecules. 2021;26(7):1880. doi:10.3390/molecules26071880